Reference priceCNY ¥630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Elahere |
|---|---|
| Manufacturer | ImmunoGen Inc |
| Prescription required | Yes |
Elahere 5mg/ml injection 1vial x 20ml (mirvetuximab soravtansine-gynx)
mirvetuximab soravtansine-gynx
Description
Elahere 5mg/ml injection 1vial x 20ml (mirvetuximab soravtansine-gynx) is a medicine catalog record in the MediPriceHub database. Active ingredient: mirvetuximab soravtansine-gynx. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: ImmunoGen Inc. Therapeutic category: Medicine Library > Oncology Medicines > Ovarian cancer drugs. Pack information: 100 / 20 (5 / ). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ]. ELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.How to Use
Use mirvetuximab soravtansine-gynx under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: mirvetuximab soravtansine-gynx. Pack size: 100 / 20 (5 / ). Pack unit: bottle. Manufacturer: ImmunoGen Inc. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Ovarian cancer drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.以上内容仅供参考。使用药品前请咨询合格的医疗专业人士。